rp 73401 has been researched along with cilomilast in 14 studies
| Studies (rp 73401) | Trials (rp 73401) | Recent Studies (post-2010) (rp 73401) | Studies (cilomilast) | Trials (cilomilast) | Recent Studies (post-2010) (cilomilast) |
|---|---|---|---|---|---|
| 92 | 0 | 23 | 162 | 13 | 42 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (14.29) | 18.2507 |
| 2000's | 8 (57.14) | 29.6817 |
| 2010's | 3 (21.43) | 24.3611 |
| 2020's | 1 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Andresen, CJ; Cheng, JB; Cohan, VL; Decker, C; DiCapua, FM; Duplantier, AJ; Johnson, KL; Kraus, KG; Turner, CR; UmLand, JP; Watson, JW; Wester, RT; Williams, AS; Williams, JA | 1 |
| Ferlenga, P; Marchini, F; Morazzoni, G; Napoletano, M; Norcini, G; Pellacini, F; Pradella, L | 1 |
| Fattori, R; Ferlenga, P; Marchini, F; Morazzoni, G; Napoletano, M; Norcini, G; Pellacini, F; Pradella, L | 1 |
| Alonso, JM; Andrés, JI; Boeckx, G; Cools, M; de Chaffoy, D; De Clerck, F; Deroose, F; Díaz, A; Diels, G; Fernández, J; Freyne, EJ; Iturrino, L; Martínez, P; Matesanz, E; Megens, A; Peeters, D; Petit, D; Somers, M; Stoppie, P; Van Wauwe, J | 1 |
| Artis, DR; Bollag, G; Card, GL; England, BP; Fong, D; Gillette, S; Ibrahim, PN; Kim, SH; Lee, B; Luu, C; Milburn, MV; Powell, B; Schlessinger, J; Suzuki, Y; Tabrizizad, M; Zhang, KY | 1 |
| Bachert, EL; Cheng, JB; Cohan, VL; Duplantier, AJ; Jenkinson, TH; Kraus, KG; McKechney, MW; Pillar, JD; Watson, JW | 1 |
| Barlow, DJ; Ehrman, TM; Hylands, PJ | 1 |
| de Esch, IJ; de Graaf, C; Jansen, C; Kanev, GK; Kooistra, AJ; Leurs, R | 1 |
| He, J; Ke, H; Peng, T; Qi, B; Shi, J | 1 |
| Au, BT; Collins, PD; Teixeira, MM; Williams, TJ | 1 |
| Ezeamuzie, CI | 1 |
| Dai, YR; Xia, XD; Xu, ZJ | 1 |
| Beume, R; Bundschuh, DS; Marx, D; Wohlsen, A; Wollin, L | 1 |
| Barg, M; Geerts, A; Quednau, R; Tersteegen, A; Wunder, F | 1 |
2 review(s) available for rp 73401 and cilomilast
| Article | Year |
|---|---|
Advances in the Development of Phosphodiesterase-4 Inhibitors.
Topics: Animals; Cyclic Nucleotide Phosphodiesterases, Type 4; Drug Development; Drug Discovery; Humans; Molecular Structure; Phosphodiesterase 4 Inhibitors; Protein Conformation; Quinolones; Vomiting | 2020 |
[Phosphosdiesterase 4 inhibitors in the treatment of pulmonary diseases].
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Aminopyridines; Asthma; Benzamides; Bronchodilator Agents; Carboxylic Acids; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclohexanecarboxylic Acids; Cyclopropanes; Humans; Lung Diseases; Nitriles; Phosphodiesterase Inhibitors; Pulmonary Disease, Chronic Obstructive; Pyridines | 2004 |
12 other study(ies) available for rp 73401 and cilomilast
| Article | Year |
|---|---|
7-Oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridines as novel inhibitors of human eosinophil phosphodiesterase.
Topics: Airway Obstruction; Animals; Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Steroidal; Bronchoalveolar Lavage Fluid; Cell Count; Cell Line; Cyclic AMP; Cytokines; Dihydropyridines; Drug Evaluation, Preclinical; Eosinophils; Guinea Pigs; Humans; In Vitro Techniques; Isoenzymes; Macaca fascicularis; Molecular Conformation; Neutrophils; Ovalbumin; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Pyrazoles; Pyrrolidinones; Rolipram; Structure-Activity Relationship | 1998 |
Phthalazine PDE4 inhibitors. Part 2: the synthesis and biological evaluation of 6-methoxy-1,4-disubstituted derivatives.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Benzamides; Biological Availability; Cyclic Nucleotide Phosphodiesterases, Type 4; Enzyme Inhibitors; Guinea Pigs; Humans; Inhibitory Concentration 50; Molecular Structure; Monocytes; Neutrophils; Phthalazines; Protein Binding; Pyridines; Rolipram; Tumor Necrosis Factor-alpha | 2001 |
Phthalazine PDE4 inhibitors. Part 3: the synthesis and in vitro evaluation of derivatives with a hydrogen bond acceptor.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Binding Sites; Cyclic Nucleotide Phosphodiesterases, Type 4; Drug Design; Drug Evaluation, Preclinical; Humans; Hydrogen Bonding; Neutrophils; Phosphodiesterase Inhibitors; Phthalazines; Rolipram; Structure-Activity Relationship | 2002 |
Synthesis and biological evaluation of imidazol-2-one and 2-cyanoiminoimidazole derivatives: novel series of PDE4 inhibitors.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Administration, Topical; Animals; Anti-Inflammatory Agents; Cyclic Nucleotide Phosphodiesterases, Type 4; Disease Models, Animal; Dose-Response Relationship, Drug; Ear Diseases; Enzyme Inhibitors; Humans; Imidazoles; Inflammation; Inhibitory Concentration 50; Rats; Structure-Activity Relationship | 2002 |
Structural basis for the activity of drugs that inhibit phosphodiesterases.
Topics: Binding Sites; Crystallography, X-Ray; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Protein Structure, Tertiary | 2004 |
SAR of a series of 5,6-dihydro-(9H)-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-alpha]pyridines as potent inhibitors of human eosinophil phosphodiesterase.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Biological Availability; Cyclic Nucleotide Phosphodiesterases, Type 4; Dogs; Eosinophils; Female; Ferrets; Heterocyclic Compounds, 3-Ring; Humans; In Vitro Techniques; Isoenzymes; Male; Phosphodiesterase Inhibitors; Pyrazoles; Pyridines; Rats; Recombinant Proteins; Structure-Activity Relationship; Triazoles; Vomiting | 2007 |
In silico search for multi-target anti-inflammatories in Chinese herbs and formulas.
Topics: Anti-Inflammatory Agents; Crystallography, X-Ray; Cyclooxygenase 1; Cyclooxygenase 2; Databases, Factual; Drug Design; Drugs, Chinese Herbal; Enzyme Inhibitors; JNK Mitogen-Activated Protein Kinases; Medicine, Chinese Traditional; Models, Chemical; Models, Molecular; Molecular Conformation; p38 Mitogen-Activated Protein Kinases; Phosphodiesterase 4 Inhibitors; Structure-Activity Relationship | 2010 |
PDEStrIAn: A Phosphodiesterase Structure and Ligand Interaction Annotated Database As a Tool for Structure-Based Drug Design.
Topics: Databases, Protein; Dose-Response Relationship, Drug; Drug Design; Humans; Ligands; Models, Molecular; Molecular Structure; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Structure-Activity Relationship | 2016 |
Effect of PDE4 inhibitors on zymosan-induced IL-8 release from human neutrophils: synergism with prostanoids and salbutamol.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Adult; Albuterol; Benzamides; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclohexanecarboxylic Acids; Drug Synergism; Humans; Interleukin-8; Neutrophils; Nitriles; Phosphodiesterase Inhibitors; Prostaglandins; Pyridines; Pyrrolidinones; Rolipram; Zymosan | 1998 |
Requirement of additional adenylate cyclase activation for the inhibition of human eosinophil degranulation by phosphodiesterase IV inhibitors.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Adenylyl Cyclases; Adult; Albuterol; Benzamides; Cell Degranulation; Colforsin; Cyclic AMP; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclohexanecarboxylic Acids; Dinoprostone; Dose-Response Relationship, Drug; Enzyme Activation; Eosinophil Peroxidase; Eosinophils; Histamine; Humans; Nitriles; Peroxidases; Phosphodiesterase Inhibitors; Pyridines; Rolipram; Superoxides; Theophylline | 2001 |
Inhibition of airway hyperresponsiveness and pulmonary inflammation by roflumilast and other PDE4 inhibitors.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Administration, Oral; Aminopyridines; Animals; Benzamides; Bronchial Spasm; Bronchoalveolar Lavage Fluid; Carboxylic Acids; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclohexanecarboxylic Acids; Cyclopropanes; Disease Models, Animal; Immunization; Male; Neutrophils; Nitriles; Ovalbumin; Phosphodiesterase Inhibitors; Pneumonia; Pyridines; Rats; Respiratory Hypersensitivity; Rolipram; Serotonin; Treatment Outcome; Tumor Necrosis Factor-alpha | 2006 |
Characterization of the cellular activity of PDE 4 inhibitors using two novel PDE 4 reporter cell lines.
Topics: Aminopyridines; Animals; Benzamides; CHO Cells; Cricetulus; Cyclic AMP; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclic Nucleotide-Gated Cation Channels; Cyclohexanecarboxylic Acids; Cyclopropanes; Humans; Models, Biological; Nitriles; Phosphodiesterase 4 Inhibitors; Pyridines; Receptors, Adrenergic, beta-1; Reverse Transcriptase Polymerase Chain Reaction | 2013 |